Clinical Scorecard: Progress in Hemophilia Management: From Genetic Discoveries to Ideal Treatments by 2025

At a Glance

Key Highlights

• Introduction of recombinant factor concentrates and non-factor replacement therapies
• 70% of patients globally lack access to adequate treatment
• Emergence of gene therapy as a transformative prospect
• Pharmacokinetic modeling for optimized treatment regimens
• Focus on global inequity in hemophilia care

Guideline-Based Recommendations

Diagnosis

• Neonatal diagnosis and genetic insights for hemophilia

Management

• Factor replacement therapy remains the cornerstone of management
• Use of extended half-life products and non-factor therapies to improve adherence

Monitoring & Follow-up

• Long-term outcomes and pharmacokinetic optimization across the lifespan

Risks

• Risk of inhibitor formation with factor replacement therapy
• Immunological responses to viral vectors in gene therapy

Patient & Prescribing Data

Patients with hemophilia A and B, including pediatric populations

Weight-normalized clearance in children affects dosing frequency

Clinical Best Practices

• Address global inequities in access to hemophilia treatments
• Incorporate pharmacokinetic modeling for personalized treatment plans
• Monitor long-term outcomes of new therapies

Related Resources & Content

• Dushimova et al. Review on Hemophilia Management
• Kao et al. Non-viral Gene Therapy for Hemophilia A
• Terasaka and McKeand on Pharmacokinetic Modeling